MIRA Company Profile and Key Details

MIRA Pharmaceuticals, Inc. generated EPS of -$1.52 over the past year. Five-year average earnings growth is -224.25%. MIRA Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended March 31, 2026, missed forecasts by 275.0%. The prior quarter beat by 1375.0%. Over the last six quarters, Apple has recorded several small beats. These include -48.28% in March 28, 2025.

Short-term trend indicators are bullishly aligned (SMA20 9.44%, SMA50 -3.03%, SMA200 -5.29%). The stock’s 14-day RSI is 56.74 (neutral), while the ATR of 0.07 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -45.71% below its high and over 82.19% above its low. Average 10-day trading volume of 54.40 thousand shares is below the 3-month average of 97.04 thousand, indicating normal recent market interest.

MIRA Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.27. This means the shares are trading above this model’s fair value.

MIRA Pharmaceuticals, Inc. has 19.07 million shares outstanding. The public float is 14.67 million shares, elevated short interest at 2.66% of float. This equals 388.88 thousand shares. The short ratio is 0.12 days. Institutional investors hold 6.03% of the float. Insiders own 16.71%.

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) closed at $0.76 USD, gaining $0.05 (7.53%) from the previous close of $0.71. The stock is currently mid-range between its 52-week high and low $0.60 and $2.45. With a market capitalization of about $32.09 million, MIRA Pharmaceuticals, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.55). Key stats such as the average daily volume over the past year has been around 98.61 thousand shares, in line with its 52-week average. Headquartered in Miami, FL, MIRA Pharmaceuticals, Inc. operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Erez Aminov, the company employs approximately 2 people and listed since August 03, 2023. MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase.

MIRA Pharmaceuticals, Inc. trades at a P/E ratio of -0.55, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.94 trading at moderately above to book value. The P/FCF stands at -6.93, also below market averages.

Our AI price prediction model suggests that MIRA Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -14.88%, with price expected at $0.65 by September 03, 2026, within a range of $0.58 to $0.73 3-Month Outlook: Projected fall of -41.07%, reaching $0.45 by November 18, 2026, with a range of $0.41 to $0.48. 1-Year Outlook: Projected loss of -60.71%, with price at $0.30 by August 20, 2027, within a range of $0.00 to $0.23.

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) shares are flat -3.97% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows MIRA Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -0.55. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $17.00, suggesting 2126.3% upside. Our AI forecast model points to short-term weakness (-14.88% over two weeks), a medium-term fall (-41.07% over three months), and a longer-term loss (-60.71% over one year), with expected trading ranges indicating moderate volatility.